Trial Profile
Phase I/II Study of Low-Dose Cyclophosphamide, Tumor Associated Peptide Antigen-Pulsed Dendritic Cell Therapy and Low Dose GM-CSF, As Consolidation Treatment in Patients With Hematologic Malignancies
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 19 Jul 2023
Price :
$35
*
At a glance
- Drugs KiroVAX 001 (Primary) ; KiroVAX 001 (Primary) ; Cyclophosphamide; Granulocyte macrophage colony stimulating factor
- Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Haematological malignancies; Hodgkin's disease; Multiple myeloma; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Sponsors Kiromic
- 10 Oct 2019 Planned initiation date changed from 1 Dec 2016 to 28 Jul 2017.
- 10 Oct 2019 Status has been changed to withdrawn prior to enrolment.
- 13 Aug 2019 Planned End Date changed from 31 Jan 2019 to 31 Oct 2020.